A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
- Solid Tumors
- United Kingdom
- United States
NCT05129280 2021-000624-35 BE43244
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A*02:01 allele.
An Open-label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
- Unresectable and/or metastatic solid tumors that have received standard-of-care (SOC) therapies previously and have no other SOC options available
- Confirmed HLA-A*02:01 haplotype
- Confirmed MAGE-A4 expression
- Radiologically measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Life expectancy of >/=12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Absence of rapid disease progression, threat to vital organs or non-irradiated lesions >2 cm in diameter at critical sites
- No significant ongoing toxicity from prior anticancer treatment
- Adequate hematological function
- Adequate liver function
- Adequate renal function
- If applicable, willingness to use contraceptive measures.
- History or clinical evidence of CNS primary tumors or metastases
- Another invasive malignancy in the last 2 years
- Uncontrolled hypertension
- Significant cardiovascular disease
- Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic or other infection
- Current or past history of CNS disease
- Dementia or altered mental status that would prohibit informed consent
- Active auto-immune disease or flare within 6 months prior to start of study treatment
- Expected need for regular immunosuppressive therapy or with systemic corticosteroids
- Insufficient washout from prior anti-cancer therapy
- Prior treatment with a bispecific T-cell engaging or adoptive cell therapy.
For the latest version of this information please go to www.forpatients.roche.com